多西紫杉醇联合卡培他滨治疗转移性乳腺癌的疗效分析  

Clinical Efficacy of Docetaxel Combined with Capecitabine on Metastatic Breast Cancer

作　　者：任洁 

机构地区：[1]长江航运总医院肿瘤科,430010

出　　处：《实用癌症杂志》2013年第6期649-651,共3页The Practical Journal of Cancer

摘　　要：目的探讨多西紫杉醇联合卡培他滨(DC方案)治疗转移性乳腺癌的临床疗效。方法选择79例转移性乳腺癌患者,均采用DC方案化疗,然后评价患者的临床疗效及不良反应。结果 79例患者在本研究中共完成300个化疗周期,中位化疗周期数3.8个。总有效率为50.6%,其中CR 3例(3.8%)。化疗主要不良反应有乏力、骨髓抑制、手足综合征、胃肠道反应、口腔黏膜炎等。65例患者出现中性粒细胞下降,其中5例达Ⅳ度骨髓抑制。中位随访时间为10.5个月,中位无进展生存期(progression-free survival,PFS)为5.8个月。结论多西紫杉醇联合卡培他滨方案治疗转移性乳腺癌的有效率高,疗效肯定,不良反应可以耐受,是治疗转移性乳腺癌的有效方案。Objective To evaluate the efficacy of docetaxel and capecitabine combination chemotherapy（DC regimen） for patients with metastatic breast cancer. Methods 79 patients with metastatic breast cancer were treated with docetaxel and capecitabine combination regimen. The curative effect and adverse reactions were evaluated after chemotherapy. Results A total of 300 cycles of DC regimen were administered, with a median of 3.8 cycles. The total response rate was 50.6% ,with a complete remission（CR） rate of 3.8%. The most frequent treatment-related adverse reactions were fatigue, myelosuppression, hand-foot syndrome,gastrointestinal reaction,and oral mucositis, etc. Neutropenia was observed in 65 patients. 5 patients developed degree IV myelosuppression. The median follow-up was 10.5 months, and the median progression-free survival was 5.8 months. Conclusion The combination of docetaxel and capecitabine provides a well-tolerated and effective chemotherapy regimen for metastatic breast cancer.

关 键 词：乳腺癌 多西紫杉醇 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]